StockStory Flags Clorox’s Sales and Cash-Flow Weaknesses
The publisher points to declining sales, modest organic growth and a lower free-cash-flow margin in its cautious assessment of Clorox.
Key takeaways
- StockStory said Clorox sales fell at a 3.1% annual rate over three years.
- The company’s trailing-12-month free-cash-flow margin was 6%, according to StockStory.
StockStory said Clorox’s business fell short of its standards, citing declining sales and a lower free-cash-flow margin. The publisher noted the shares had lost 19% over six months, while the S&P 500 gained 12.8%.
StockStory said Clorox sales fell at a 3.1% annual rate over three years. Organic revenue growth averaged 1.7% year over year across the last eight quarters, and the trailing-12-month free-cash-flow margin was 6%, down 4.7 percentage points over the prior year.
The publisher described the stock’s valuation as reasonable but said it saw little opportunity. As of 20:00 UTC on Oct. 12, shares traded at $84.35, up 0.66% from the previous close.
This article was produced with the help of AI technology. Source: Yahoo Finance
